Dr. Peter Wilson is an expert in translational oncology with over 20 years of experience in cancer research and drug development. As Director of Science and Drug Development at CV6 Therapeutics (NI) Ltd. since 2014, he leads preclinical strategy and therapeutic development, focusing on overcoming resistance to widely used cancer treatments.

Dr. Wilson’s research has centered on cellular signaling and drug resistance mechanisms, particularly within nucleotide biosynthesis pathways. He has identified novel drug targets and developed a proprietary screening platform to accelerate the discovery of new therapeutic candidates. His work has contributed to the advancement of multiple programs into clinical development.

Previously, Dr. Wilson was a key member of a translational research initiative at the University of Southern California (USC) Norris Comprehensive Cancer Center. There, he directed preclinical efforts that led to two Phase I biomarker-integrated clinical trials in advanced colorectal cancer.

Dr. Wilson holds a BSc (Hons) in Genetics and a PhD in Molecular Oncology from Queen’s University Belfast, where he trained under the mentorship of Professor Patrick G. Johnston. His PhD was supported by a Northern Ireland Health and Personal Social Services Research and Development Studentship.